Global Generics Pharma Leader Selects Kneat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2025
0mins
Should l Buy ?
Source: Newsfilter
Kneat's New Partnership: Kneat.com, inc. has signed a Services Agreement with a multinational generic pharmaceuticals producer to digitalize its drawing management process, enhancing efficiency and accuracy in engineering and validation workflows.
Customer Satisfaction and Growth: Kneat has achieved strong customer retention, with a net revenue retention rate of 151% as of December 31, 2024, and boasts high customer satisfaction ratings, positioning itself as a leader in the life sciences validation software market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
